Second Sight Medical Products Inc employing SYMBOL code NASDAQ:EYES had its stockpile rating indicated as “Coverage Initiated” with the suggestion being established at “buy” this morning by the analysts named H.C. Wainwright. Second Sight Medical Products Inc seems to be listed in the sector of health care within NASDA.
The analyst H.C. Wainwright has established their target price rate to 21 USD in its stock. This in turn indicates the analyst that there has been a potential upside of 44.8 percent from its beginning price value of 14.5 USA. Second Sight Medical Products Inc with its symbol code NASDAQ:EYES possess a 50-day moving average of about 13.92 USB as well as a 200-day moving average share price which is recorded at 13.56 USD. However, the 52-week high share cost is 24.02 USD whereas the low-price of the year is considered to be currently 8.05 USD.
About The Second Sight Medical Products Manufacturer:
Second Sight Medical Products Inc that employs symbol code NASDAQ:EYES seems to be a reputed medical device sector which manufactures, develops as well as markets visual implantable prosthetics in order to restore some functional vision for the blind patients. The company’s products comprises of the Argus II System that aids in treating the external retinal degenerations like retinitis pigmentosa or RP. Moreover, the Argus II System offers with an artificial system of vision which differs from the normal sighted vision which people usually have.
The Argus II Retinal Prosthesis System comprises of implant, pair of glasses and a small portable computer with a minute small video camera. Besides from that, The Argus II system to CE or Conformite Europeenne mark approval for sales and marketing in the European Union EU, and hence approval by FDA or united states food and drug administration for sales and marketing in united state. Other than that, the country also markets Argus II system in turkey, Canada as well as at one specific medical center in Saudi Arabia.
The Second Sight Medical Products, Inc was founded in the year 1998 and it is headquatered in the location of Sylmar at California. The company sells its Argus II system to teaching hospitals, university hospitals, medical centers as well as ambulatory surgical centers. The company also provides Argus II System which serves as an implantable neuro-stimulation device which makes use of electrical stimulation towards retina in order to restore the function of outdated photo-receptions in patients suffering from retinitis pigmentosa.